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 Faecal calprotectin (FC) - reliable and non-invasive stool biomarker used to 
monitor inflammation in inflammatory bowel disease (IBD) 
 Routinely performed by ELISA (time consuming and costly). 
 QuantonCal is an immunologic rapid test that  measures calprotectin via a 
lateral flow device to a smart phone. Designed for use by patient at home  
 Delivers  result within 15 minutes.  
 We sought to compare the accuracy, usability and patient perception of 
QuantonCal against ELISA.  
 
 Patients attending outpatient clinic at the Royal Devon and Exeter Hospital, 
UK approached 
 Inclusion criteria: owning a smartphone and need for disease 
activity/inflammation assessment  
 Patients collected a stool sample to perform QuantonCal and submitted a 
sample for ELISA analysis to assess correlation.  
 Patients also invited to complete questionnaire regarding the usability of 
QuantonCal.  
 Laboratory calprotectin (LC) readings >250µg/L as gold standard 
 
 
 59 patients: 32 CD, 23 UC, 4 IBD-U.  
 38 (64%) submitted at least one sample for analysis, 26 (44%) 
submitted two samples. Three QuantonCal samples were excluded 
for invalid readings. 
 QuantonCal and LC readings  significantly correlated; Spearman’s 
rank correlation coefficient = 0.737, p <0.005 (figure 1), however 
QuantonCal  overestimated the LC value by about 70%.  
 Median QuantonCal FC was 385 µg/g [IQR 31 – 1850], median 
laboratory FC was 148 µg/g [IQR 46 – 529] 
 QuantonCal test performance: area under the curve (AUC) = 0.870 
(95% confidence interval (CI) = 0.779 – 0.961), sensitivity 90%, 
specificity 78%, positive predictive value (PPV) 70%, and negative 
predictive value (NPV) 94%. 
 Of 26 patients that submitted two sets of samples, the change in 
calprotectin was compared between readings. Of 26 participants, 7 
(27%) where the laboratory calprotectin reading rose, the 
QuantonCal value fell, or vice versa (figure 2). 
  24 patients completed the satisfaction questionnaire. Acceptability 
was high: 15 (63%) thought the QuantonCal application was ‘very 
easy’, 7 (29%) ‘easy’,. No patients reported the application was 
‘difficult’ or ‘very difficult’ to use. 
 Preference towards QuantonCal compared to laboratory test: equal 
preference 9 (37%), slight preference for iPhone 7 (29%) and strong 
preference for iPhone 4 (17%)  
 
 QuantonCal shows promise with values that correlate to LC. 
However, 27% of serial readings had disparate results. Clinically, this 
would either lead to delayed treatment, or inappropriate escalation 
of therapy. Patient acceptability remains high with slight preferences 
towards home testing. This study assumes LC as the gold standard but 
future studies could use endoscopy for comparison.  
Figure 1: Correlation of home calprotectin values 
to laboratory calprotectin  
 
Figure 2: Serial calprotectin values: QuantonCal against LC 
Note values inside pink boxes have disparate results  
 
